메뉴 건너뛰기




Volumn 194, Issue , 2013, Pages 479-485

PRRT as neoadjuvant treatment in NET

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; FLUOROURACIL; KI 67 ANTIGEN; LUTETIUM TETRAXETAN OCTREOTIDE[3 TYROSINE] LU 177; UNCLASSIFIED DRUG; YTTRIUM TETRAXETAN OCTREOTIDE[3 TYROSINE] Y 90;

EID: 84867037559     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_27     Document Type: Review
Times cited : (17)

References (10)
  • 1
    • 83955165920 scopus 로고    scopus 로고
    • The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumors resectable
    • Barber TW, Hofman MS, Thomson BN et al (2012) The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumors resectable. Eur J Surg Oncol 38:64-71
    • (2012) Eur J Surg Oncol , vol.38 , pp. 64-71
    • Barber, T.W.1    Hofman, M.S.2    Thomson, B.N.3
  • 2
    • 33750592324 scopus 로고    scopus 로고
    • Dosimetry in peptide radionuclide receptor therapy: A review
    • Cremonesi M, Ferrari M, Bodei L et al (2006) Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 47:467-1475
    • (2006) J Nucl Med , vol.47 , pp. 467-1475
    • Cremonesi, M.1    Ferrari, M.2    Bodei, L.3
  • 3
    • 0043132282 scopus 로고    scopus 로고
    • Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group
    • DOI 10.1200/JCO.2003.12.142
    • Faiss S, Pape UF, Bohming M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the international lanreotide and interferon alfa study group. J Clin Oncol 21:2689-2696 (Pubitemid 46606312)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.14 , pp. 2689-2696
    • Faiss, S.1    Pape, U.-F.2    Bohmig, M.3    Dorffel, Y.4    Mansmann, U.5    Golder, W.6    Riecken, E.O.7    Wiedenmann, B.8
  • 4
    • 74049086575 scopus 로고    scopus 로고
    • Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
    • Kaemmerer D, Prasad V, DaffnerWet al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15:5867-5870
    • (2009) World J Gastroenterol , vol.15 , pp. 5867-5870
    • Kaemmerer, D.1    Prasad, V.2    Daffner, W.3
  • 5
    • 33747589429 scopus 로고    scopus 로고
    • Resection of pancreatic neuroendocrine tumors: Results of 70 cases
    • DOI 10.1001/archsurg.141.8.765
    • Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: Results of 70 cases. Arch Surg 141:765-769 (Pubitemid 44268515)
    • (2006) Archives of Surgery , vol.141 , Issue.8 , pp. 765-769
    • Kazanjian, K.K.1    Reber, H.A.2    Hines, O.J.3
  • 6
    • 70049091797 scopus 로고    scopus 로고
    • Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management
    • Nomura N, Fujii T, Kanazumi N et al (2009) Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management. J Hepatobiliary Pancreat Surgery 16:639-647
    • (2009) J Hepatobiliary Pancreat Surgery , vol.16 , pp. 639-647
    • Nomura, N.1    Fujii, T.2    Kanazumi, N.3
  • 8
    • 70350442637 scopus 로고    scopus 로고
    • Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumor: A report from the PROMID study group
    • Rinke A, Muller HH, Schade- Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumor: A report from the PROMID study group. J Clin Oncol 27:4656-4663
    • (2009) J Clin Oncol , vol.27 , pp. 4656-4663
    • Rinke, A.1    Muller, H.H.2    Schade-Brittinger, C.3
  • 9
    • 80455174802 scopus 로고    scopus 로고
    • Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)
    • Sowa-Staszczak A, Pach D, Chrzan R et al (2011) Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs). Eur J Nucl Med Mol Imaging 38:1669-1674
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 1669-1674
    • Sowa-Staszczak, A.1    Pach, D.2    Chrzan, R.3
  • 10
    • 77950890318 scopus 로고    scopus 로고
    • Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor
    • Stoeltzing O, Loss M, Huber M et al (2010) Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395:185-192
    • (2010) Langenbecks Arch Surg , vol.395 , pp. 185-192
    • Stoeltzing, O.1    Loss, M.2    Huber, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.